An Alliance To Advance Understanding Of Cancer-Related Neuropathic Pain
University of Texas M. D. Anderson Cancer Center, AstraZeneca will collaborate to help advance understanding of neuropathic pain caused by cancer chemotherapy, a side effect that often limits optimal therapeutic dosing in cancer treatments.
The new alliance will focus on identifying neurobiological differences between cancer patients who develop chemotherapy-induced pain and patients who experience little or no pain. Scientists at M. D. Anderson and AstraZeneca hope to better understand the mechanisms through which chemotherapies cause peripheral nerve dysfunctions, such as numbness and tingling, and severe pain. Research could lead to new treatments to prevent pain -- extending the therapeutic value of current chemotherapies -- as well as help in the development of new chemotherapies with less severe pain-related side effects.
"Our collaboration with AstraZeneca addresses a critical need in cancer care, which is improving the quality of life of cancer patients," said Dr. Charles Cleeland, chair of M. D. Anderson's Department of Symptom Research.
M. D. Anderson and AstraZeneca have ongoing collaborations focused on a variety of initiatives across a range of AstraZeneca oncology products and research projects. This new agreement will extend that relationship to examine one of the most prevalent symptoms in cancer patients. One study found that pain affects up to 50 percent of patients undergoing active cancer treatment and up to 90 percent of those with advanced disease.
"Our experience in establishing a strategic alliance in 2006 to accelerate the evaluation and approval of anti-cancer drugs can now be extended to more effective supportive care for cancer patients and individuals with other diseases," said Dr. Robert Bast, Vice President of Translational Research at M. D. Anderson.
"We are excited to begin this collaboration with M. D. Anderson, which is at the forefront of discovering new ways of assessing and addressing pain symptoms associated with cancer treatment," said Bob Holland, Vice President for Neuroscience at AstraZeneca. "We hope the insights we gain from this alliance will ultimately lead to new treatment options that will improve the quality of life for cancer patients."
"We are hopeful that the knowledge gained from this collaboration will enable us to design and validate new pain research models that can then be used to effectively test novel therapies in a preclinical setting," said Andy Dray, Chief Scientist in the CNS and Pain Research Area at AstraZeneca.
This is the third of several planned new alliances by AstraZeneca with leading academic and research institutions to address unmet medical needs through cutting-edge research across several disease areas, including Alzheimer's disease, chronic pain and psychiatric illnesses. These proposed new agreements complement existing AstraZeneca US-based alliances in neuroscience and other key therapeutic areas with world-class institutions.